Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0XI3E
|
|||
| Drug Name |
INCB01158
|
|||
| Synonyms |
CB-1158
Click to Show/Hide
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1/2 | [1] | |
| Company |
Calithera Biosciences; Incyte
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Arginase (ARG) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03837509) INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.